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Abstract
To understand the molecular mechanisms that determine the fate of a cell to undergo either hypertrophy or hyperplasia,
we studied the effects of angiotensin II (Ang II) and platelet-derived growth factor (PDGF)-BB, hypertrophic and
hyperplastic agents, respectively, on the modulation of G1/S transition molecules in smooth muscle cells. Ang II increased
protein synthesis while PDGF-BB induced both DNA and protein synthesis. Ang II had no significant effect on the steady-
state levels of cyclin-dependent kinase (CDK) inhibitor (CDKI), p27kip1, and on the activities of CDK2 and CDK4, although
it caused a modest increase in cyclin E levels. In contrast, PDGF-BB induced depletion of p27kip1 and increased cyclins D1
and E levels and CDK2 and CDK4 activities. Reflecting its lack of effect on CDK activities, Ang II failed to phosphorylate
tumor suppressor retinoblastoma protein, Rb. PDGF-BB, on the other hand, induced phosphorylation of Rb, consistent
with its ability to activate CDKs. Together, these findings suggest that Ang II-induced hypertrophy may be due to its failure
to activate cellular signaling events required for G1/S transition. ß 1999 Elsevier Science B.V. All rights reserved.
Keywords: Angiotensin II; Cyclin dependent kinase; Protein synthesis ; G1/S transition; Platelet-derived growth factor
1. Introduction
Angiotensin II (Ang II) often causes hypertrophy
(increase in cell size without a change in cell number)
in vascular smooth muscle cells (VSMC) [1,2]. Earlier
reports from several laboratories including ours
showed that Ang II is a potent activator of immedi-
ate early signaling events [3^7]. Speci¢cally, Ang II
induced the phosphorylation of ribosomal S6 protein
and protein synthesis initiation factor, eIF4E [3,4];
increased c-fos and c-myc expression; and activated
extracellular signal-regulated kinases [5^7]. Despite
its ability to mimic mitogens in activating these im-
mediate early response events, Ang II causes only
hypertrophy but not hyperplasia in VSMC.
Cyclin-dependent kinases (CDKs), a group of ser-
ine/threonine kinases, play a determinant role in cell
cycle progression [8^10]. CDKs were thought to con-
nect mitogen-induced immediate early response sig-
nals with delayed cellular e¡ects such as DNA syn-
thesis [10]. CDK activities, in turn, are regulated by
positive and negative modulators of the cell cycle,
cyclins and CDK inhibitors (CDKIs), respectively
[8^10]. CDK4, for example, requires association
with type D cyclins for its activity as does CDK2
with cyclin E [11^13]. CDK activities are also regu-
lated by phosphorylation and dephosphorylation
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[14]. The negative regulation of CDKs depends on
their association with and on the levels of CDKIs
[15^17]. In fact, transforming growth factor L
(TGF-L) and cAMP-inhibited growth in some cell
types was reportedly due to induced expression of
CDKI p27kip1 and its interference with cyclin
E-CDK2 and cyclin D1-CDK4 activities, respectively
[18,19]. Among the known classes of cyclins and
CDKs, cyclin E-CDK2 has been shown to play a
rate-limiting role in G1/S transition [11,12]. To gain
more insight into the signaling events underlying
hypertrophy, we studied the e¡ect of Ang II on the
modulation of G1/S transition molecules. We found
that Ang II had no signi¢cant e¡ect on steady-state
levels of p27kip1, and on CDK2 and CDK4 activities
and Rb phosphorylation. On the other hand, a hy-
perplastic agent, platelet-derived growth factor
(PDGF)-BB, caused signi¢cant depletion of p27kip1
and increased CDK2 and CDK4 activities and Rb
phosphorylation. These ¢ndings suggest that hyper-
trophic agents such as Ang II are unable to activate
signals that are necessary for the cell to enter into the
S phase, and, therefore, cause hypertrophy.
2. Materials and methods
2.1. Materials
Angiotensin II, aprotinin, ATP, EGTA, L-glycero-
phosphate, leupeptin, phenylmethylsulfonyl £uoride
(PMSF) and sodium orthovanadate were obtained
from Sigma Chemical Co. (St. Louis, MO). PDGF-
BB was from Genzyme (Cambridge, MA). Anti-
CDK2 (sc-163), CDK4 (sc-260), cyclin D1 (sc-246),
cyclin E (sc-481), p21waf1=cip1 (sc-397), p27kip1 (sc-528)
and Rb (sc-50) rabbit polyclonal antibodies, and
GST^Rb (sc-4112) recombinant fusion protein were
from Santa Cruz Biotechnology (Santa Cruz, CA).
Rb (14001A) and p21waf1=cip1 (65951A) mouse mono-
clonal antibodies were purchased from Pharmingen
(San Diego, CA). p27kip1 (K25020) mouse mono-
clonal antibodies were obtained from Transduction
Laboratories (Lexington, KY). [3H]Leucine (spec.
act. 180 Ci/mmol), [3H]thymidine (spec. act. 70 Ci/
mmol), [32P]orthophosphoric acid (spec. act. 8500 Ci/
mmol) and [Q-32P]ATP (spec. act. 8000 Ci/mmol)
were obtained from NEN-Dupont (Boston, MA).
2.2. Cell culture
VSMC were isolated from the thoracic aortae of
200^300 g male Sprague^Dawley rats by enzymatic
dissociation as described earlier [2]. Cells were grown
in Dulbecco’s modi¢ed Eagle’s medium (DMEM)
supplemented with 10% (v/v) heat-inactivated calf
serum, 100 units/ml penicillin and 100 Wg/ml strepto-
mycin. Cultures were maintained at 37‡C in a hu-
midi¢ed 95% air, 5% CO2 atmosphere.
2.3. DNA and protein synthesis
VSMC were plated onto 60-mm dishes, allowed to
grow to 70^80% con£uence and then growth-arrested
by incubating in DMEM containing 0.1% (v/v) calf
serum for 72 h. Growth-arrested VSMC were ex-
posed to Ang II (100 nM) or PDGF-BB (20 ng/ml)
for 24 h. To measure protein synthesis, 1 WCi/ml
[3H]leucine was added to VSMC immediately after
the addition of the agonist. To measure DNA syn-
thesis, cells were pulse-labeled with 1 WCi/ml
[3H]thymidine for 2 h just before the end of the
24-h incubation period. At the end of incubation,
cells were harvested by trypsinization followed by
centrifugation. The cell pellet was resuspended in
cold 10% (w/v) trichloroacetic acid (TCA) and vor-
texed vigorously to lyse the cells. The mixture was
allowed to sit on ice for 20 min and then passed
through a GF/F glass micro¢ber ¢lter. The ¢lter
was washed once with cold 5% TCA, and once
with cold 70% ethanol, and the radioactivity was
measured in a liquid scintillation counter (Beckman
LS 3801).
2.4. Western blot analysis
Growth-arrested VSMC were treated with and
without Ang II or PDGF-BB for the indicated time
periods at 37‡C. Medium was aspirated, cells were
rinsed with cold phosphate-bu¡ered saline (PBS) and
frozen immediately in liquid nitrogen. Two hundred-
¢fty Wl of lysis bu¡er (20 mM Hepes (pH 7.4),
150 mM NaCl, 1% NP-40, 10 Wg/ml aprotinin,
10 Wg/ml leupeptin, 500 WM PMSF and 1 mM so-
dium orthovanadate (Na3V04)) was added to the fro-
zen monolayers, thawed on ice for 20 min and
scraped into 1.5-ml Eppendorf tubes. The cell lysates
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were cleared by centrifugation at 12 000 rpm for 20
min at 4‡C. Protein content of the supernatants was
determined using Bio-Rad’s Bradford reagent. Cell
lysates containing equal amount of protein were re-
solved by electrophoresis on a 0.1% sodium dodecyl
sulfate (SDS) and 12% polyacrylamide gels. The pro-
tein was transferred electrophoretically to a nitrocel-
lulose membrane (Hybond, Amersham). After block-
ing in 10 mM Tris^Cl bu¡er (pH 8.0) containing
150 mM sodium chloride, 0.1% Tween-20 and 5%
(w/v) non-fat dry milk, the membrane was treated
with appropriate primary antibodies followed by in-
cubation with appropriate peroxidase-conjugated
secondary antibodies. The antigen^antibody com-
plexes were detected using chemiluminescence re-
agent kit (Amersham). Quanti¢cation of the Western
blots was done by densitometry.
2.5. Immunocomplex kinase assay
After appropriate treatments, cells were washed
with cold PBS and solubilized on ice for 15 min in
lysis bu¡er containing 20 mM Hepes (pH 7.4),
150 mM NaCl, 1% NP-40, 10 Wg/ml aprotinin,
10 Wg/ml leupeptin, 500 WM PMSF and 1 mM
Na3VO4. The cell lysates were cleared by centrifuga-
tion at 12 000 rpm for 20 min at 4‡C. Cell lysates
normalized for protein were immunoprecipitated by
incubating with anti-CDK2 or CDK4 rabbit IgG for
2 h followed by addition of 40 Wl of 50% (w/v) pro-
tein A-sepharose beads for an additional hour. The
beads were washed three times with lysis bu¡er and
three times with kinase bu¡er (25 mM Hepes (pH
7.4), 10 mM MgCl2 and 1 mM EGTA). The CDKs
activities present in the immunoprecipitates were de-
termined by resuspension in 25 Wl of kinase bu¡er
containing 4 Wg histone H1 (for CDK2 assay) (1 Wg
GST^Rb for CDK4 assay), 30 WM ATP and 5 WCi
[Q-32P]ATP, and incubating for 20 min at 37‡C. The
reaction was terminated by adding 10 Wl of
4ULaemmli sample bu¡er and heating at 95‡C for
5 min. The samples were analyzed by SDS^poly-
acrylamide gel electrophoresis (PAGE) on 12% acryl-
amide gels. The dried gel was exposed to Kodak
X-OMAT AR X-ray ¢lm with an intensifying screen
at 380‡C for 2 to 4 h, and quantitated by densitom-
etry.
2.6. Phosphorylation of Rb
Growth-arrested VSMC were labeled with 200
WCi/ml [32P]orthophosphate in phosphate-free
DMEM for 4 h. Cells were then treated with agonists
for the indicated time periods. After treatments, cells
were rinsed with cold PBS and lysed in 1 ml of lysis
bu¡er (50 mM Tris^Cl (pH 7.5), 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS) con-
taining 10 Wg/ml aprotinin, 10 Wg/ml leupeptin,
50 mM L-glycerophosphate, 500 WM phenylmethyl-
sulfonyl £uoride and 1 mM sodium orthovanadate,
for 20 min on ice. Cell lysates were collected into
1.5-ml Eppendorf tubes and cleared by centrifuga-
tion at 12 000 rpm for 20 min at 4‡C. Cell lysates
normalized for protein were incubated with 20 Wl of
Rb polyclonal antibodies for 2 h with gentle rocking
at 4‡C. Forty Wl of 50% (w/v) protein A^Sepharose
beads were added and incubation continued for an
additional hour. The beads were collected by centri-
fugation, and washed ¢ve times with cold lysis bu¡er
and once with cold PBS. The beads were then heated
in 40 Wl of Laemmli sample bu¡er for 5 min and the
immunoprecipitates were separated by electrophore-
sis on a 0.1% SDS, 8% polyacrylamide gel under
reducing conditions. The gel was dried, exposed to
X-OMAT AR X-ray ¢lm at 380‡C for 4 to 8 h, and
quantitated by densitometry.
All the experiments were repeated at least three
times with a similar pattern of results. Statistical
analysis was performed using Student’s t-test. P val-
ues less than 0.01 were considered to be signi¢cant.
3. Results and discussion
To understand the trophic e¡ects of Ang II and
PDGF-BB on VSMC growth, we measured DNA
and protein synthesis in response to these agonists.
Having no e¡ect on DNA synthesis, Ang II caused a
2.4-fold increase in protein synthesis in VSMC dur-
ing a period of 24 h as measured by [3H]leucine in-
corporation (Fig. 1). On the other hand, PDGF-BB
increased both DNA and protein synthesis by 14-
and 3-fold, respectively (Fig. 1). These results are
consistent with previous reports from several labora-
tories, including ours, that Ang II causes hypertro-
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phy and PDGF-BB causes hyperplasia in VSMC
[1,2].
To gain insight into the signaling events that
underlie Ang II-induced hypertrophic and PDGF-
BB-induced hyperplastic e¡ects in VSMC, we exam-
ined the responsiveness of G1/S transition molecules
to these agonists. Growth-arrested VSMC were
treated with Ang II (100 nM) or PDGF-BB (20 ng/
ml) for 5- or 10-h time periods, and the steady-state
levels of CDKIs p21waf1=cip1 and p27kip1 were deter-
mined by immunoblotting using their respective anti-
bodies. As shown in Fig. 2, treatment of VSMC with
Ang II for 5 h or 10 h did not a¡ect the steady-state
levels of p27kip1. PDGF-BB, on the other hand, sig-
ni¢cantly decreased (2.2-fold) the steady-state levels
of this molecule. In regard to p21waf1=cip1, Ang II had
no signi¢cant e¡ect on its steady-state levels at 5 h,
while a 1.7-fold increase was observed at 10 h. On
the other hand, PDGF-BB caused a time-dependent
increase in p21waf1=cip1 expression with 1.8- and 3-fold
at 5- and 10-h treatments, respectively. These results
show a correlation between PDGF-BB-induced
DNA synthesis and p27kip1 depletion.
To examine whether Ang II and PDGF-BB di¡er-
entially regulate positive modulators of the cell cycle,
their e¡ects on the steady-state levels of cyclins D1
and E were investigated in growth-arrested VSMC.
Ang II had no signi¢cant e¡ect on steady-state levels
of cyclin D1, but increased the expression of cyclin E
by 1.5- and 2-fold at 5 h and 10 h, respectively (Fig.
3). In contrast, PDGF-BB increased the expression
of both cyclins, albeit with di¡erent patterns. In-
creases in cyclin D1 levels in response to PDGF-
BB treatment were apparent at 5 h (1.5-fold), and
reached 3-fold by 10 h. With respect to cyclin E, a
3-fold increase in its levels were observed at 5 h
which was dropped to 2-fold by 10 h.
Earlier reports showed that p27kip1 is a negative
regulator of CDK2 and CDK4 activities and ac-
counts for TGF-L and cAMP-induced G1 arrest
[18,19]. It was also reported that cyclin E-CDK2 ac-
tivity plays a rate-limiting role in G1/S transition
[11,12]. Because Ang II and PDGF-BB di¡erentially
regulated p27kip1 and cyclins D1 and E, we wanted to
test whether these changes re£ect CDK2 and CDK4
activities in VSMC in response to these agonists. Ang
II had no signi¢cant e¡ect on either CDK2 or CDK4
activities (Fig. 4). In contrast, PDGF-BB increased
both CDK2 and CDK4 activities. A 4-fold increase
in CDK2 activity was observed after 5 h of PDGF-
BB treatment but declined thereafter to a 3-fold at
Fig. 1. E¡ect of Ang II and PDGF-BB on DNA and protein
synthesis in VSMC. Growth-arrested VSMC were treated with
and without Ang II (100 nM) or PDGF-BB (20 ng/ml) for 24 h
and the protein and DNA syntheses were measured as de-
scribed in Section 2. Results are mean þ S.D. of three independ-
ent experiments. *P6 0.01 vs. control.
Fig. 2. E¡ect of Ang II and PDGF-BB on the steady-state lev-
els of p21waf1=cip1 and p27kip1 in VSMC. Growth-arrested
VSMC were treated with and without Ang II (100 nM) or
PDGF-BB (20 ng/ml) for the indicated time periods and cell ly-
sates were prepared. Equal amount of protein from each condi-
tion was analyzed by immunoblotting for p21waf1=cip1 and
p27kip1 levels using their respective antibodies.
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10 h. A similar pattern of regulation in CDK4 activ-
ity was observed with a 2-fold increase at 5 h, and
declining thereafter (Fig. 4). To ¢nd whether di¡er-
ential activities of CDK2 and CDK4 in response to
Ang II and PDGF-BB are due to their di¡erential
expression, equal amount of protein from Ang II or
PDGF-BB-treated and untreated VSMC was ana-
lyzed by Western blotting for CDK2 and CDK4 lev-
els using their respective antibodies. No signi¢cant
changes were observed in CDK2 or CDK4 levels
between control cells and cells treated with Ang II
or PDGF-BB for 5 or 10 h.
To determine whether the changes observed in the
steady-state levels of p21waf1=cip1 and p27kip1 in
VSMC in response to Ang II and PDGF-BB also
re£ect their amounts complexed with CDK2 or
CDK4, equal amount of protein from control cells
and cells treated with Ang II or PDGF-BB for 5 h or
10 h was immunoprecipitated with anti-CDK2 or
anti-CDK4 antibodies, and these immunoprecipitates
were analyzed by immunoblotting for p21waf1=cip1 and
p27kip1 levels using their respective antibodies. Im-
munoblot analysis of anti-CDK2 and anti-CDK4 im-
munoprecipitates with anti-p21waf1=cip1 antibodies
showed no signi¢cant changes in CDK2 or CDK4-
bound p21waf1=cip1 levels between control cells and
cells treated with Ang II for 5 or 10 h or with
PDGF-BB for 5 h (Fig. 5). However, in VSMC
treated with PDGF-BB for 10 h, the CDK2 and
CDK4-bound p21waf1=cip1 levels were increased by
1.3- and 2-fold, respectively, as compared to levels
in untreated cells. In regard to p27kip1, its levels as-
sociated with CDK2 or CDK4 were not a¡ected
upon treatment of growth-arrested VSMC with
Ang II for 5 h or 10 h. CDK4-bound p27kip1 levels
also did not change between control and PDGF-BB-
treated cells. In contrast, CDK2-bound p27kip1 levels
decreased both in 5- and 10-h PDGF-BB-treated
cells as compared to its levels in untreated cells
(Fig. 5).
Tumor suppressor retinoblastoma protein, Rb,
Fig. 4. E¡ect of Ang II and PDGF-BB on CDK4 and CDK2
activities. Growth-arrested VSMC were treated with and with-
out Ang II (100 nM) or PDGF-BB (20 ng/ml) for the indicated
time periods and cell lysates were prepared. Three hundred Wg
of protein from each condition was immunoprecipitated with ei-
ther anti-CDK4 or anti-CDK2 antibodies and the kinase activ-
ities were measured in the immunocomplexes using GST^Rb fu-
sion protein and histone H1 as CDK4 and CDK2 substrates,
respectively. Equal amount of protein (30 Wg) from Ang II (100
nM)- or PDGF-BB (20 ng/ml)-treated and untreated VSMC
was analyzed by immunoblotting for CDK4 and CDK2 levels
using their respective antibodies.
Fig. 3. E¡ect of Ang II and PDGF-BB on the steady-state lev-
els of cyclins D1 and E in VSMC. Growth-arrested VSMC
were treated with and without Ang II (100 nM) or PDGF-BB
(20 ng/ml) for the indicated time periods and cell lysates were
prepared. Equal amount of protein from each condition was
analyzed by immunoblotting for cyclins D1 and E using their
respective antibodies.
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binds to and inactivates transcriptional factors,
E2Fs, that otherwise modulate expression of genes
involved in G0 to G1 progression [20,21]. Upon
phosphorylation, Rb dissociates from E2Fs enabling
them to be active. D type cyclins and their partner
CDKs such as CDK4 are implicated in the phos-
phorylation of Rb [13,22]. A role for cyclin E was
also suggested in the phosphorylation of Rb [23]. To
¢nd whether agonist-induced changes in G1 cyclin
levels and CDK activities correlate with Rb phos-
phorylation state, we measured Rb phosphorylation
in response to Ang II and PDGF-BB in growth-
arrested VSMC. Phosphorylation of Rb was meas-
ured by (1) in vivo labeling of cells with
[32P]orthophosphate followed by immunoprecipita-
tion of Rb, and (2) Western blot detection of slower
migrating hyperphosphorylated Rb than its hypo-
phosphorylated form on SDS^PAGE. Consistent
with its lack of e¡ect on CDK4 and CDK2 activities,
Ang II failed to induce Rb phosphorylation (Fig. 6,
upper panel). In contrast, PDGF-BB induced Rb
phosphorylation 4-fold by 10 h. Anti-Rb immuno-
blot analysis of anti-Rb immunoprecipitates of equal
amount of protein from control cells and cells treated
with Ang II (100 nM) or PDGF-BB (20 ng/ml) for
5 or 10 h also showed a band that migrates slower
than the hypophosphorylated Rb and reacts with
anti-Rb antibodies in 10-h PDGF-BB-treated cells
but not in control or Ang II-treated cells (Fig. 6,
lower panel). This result con¢rms the in vivo Rb
phosphorylation data. The time course of PDGF-
BB-induced Rb phosphorylation was preceded by
CDK4 and CDK2 activation.
The important ¢ndings of the present study are
that Ang II and PDGF-BB, hypertrophic and hyper-
plastic agents, respectively, di¡erentially regulated
the levels of CDKIs p21waf1=cip1 and p27kip1, cyclins
D1 and E, the activities of CDK2 and CDK4 and the
Fig. 6. E¡ect of Ang II and PDGF-BB on Rb phosphorylation.
(Upper panel) Growth-arrested and [32P]orthophosphate-labeled
VSMC were treated with Ang II (100 nM) or PDGF-BB (20
ng/ml) for the indicated times and cell lysates were prepared.
Five hundred Wg of protein from each condition was immuno-
precipitated with Rb antibodies, and the immunocomplexes
were separated by SDS^PAGE and subjected to autoradiogra-
phy. (Lower panel) Five hundred Wg of protein from Ang II
(100 nM)- or PDGF-BB(20 ng/ml)-treated and untreated
VSMC was immunoprecipitated with anti-Rb antibodies, and
the immunoprecipitates were immunoblotted with anti-Rb anti-
bodies.
Fig. 5. E¡ect of Ang II and PDGF-BB on CDK4 and CDK2-
bound p21waf1=cip1 and p27kip1 levels. Growth-arrested VSMC
were treated with and without Ang II (100 nM) or PDGF-BB
(20 ng/ml) for the indicated time periods and cell lysates were
prepared. Three hundred Wg of protein from each condition
was immunoprecipitated with either anti-CDK4 or anti-CDK2
antibodies, and the immunoprecipitates were analyzed by im-
munoblotting for p21waf1=cip1 and p27kip1 levels using their re-
spective antibodies.
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phosphorylation state of Rb in VSMC. Sequential
activation of speci¢c cyclin-CDKs is required for
an orderly progression of a cell through the cell cycle
[24,25]. For example, the requirement of activation
of cyclin D1-CDK4, cyclin E-CDK2, cyclin A-CDK2
and cyclin B1-Cdc2 (CDK1) has been reported for
progression through the G1, G1/S transition, S, and
G2/M phases of the cell cycle, respectively [11,12,24].
On the other hand, negative regulation of the cell
cycle is mediated by CDKIs [15^17,26]. Because
p27kip1 is a negative regulator of cyclin E-CDK2, a
supposedly rate-limiting kinase for G1/S transition,
and is sensitive to mitogen-induced ubiquitin^protea-
some-mediated degradation [27], it has been impli-
cated as an essential component in transmitting
growth factor-induced mitogenic signals to the cell
cycle [28]. The lack of e¡ect of Ang II on the
steady-state levels of p27kip1 and on the activities of
CDK4 and CDK2 correlate with its lack of e¡ect on
DNA synthesis in VSMC. The depletion of p27kip1
and activation of CDK4 and CDK2 also correlate
with increased DNA synthesis in PDGF-BB-treated
VSMC. It was reported that p27kip1 mediates cAMP-
induced inhibition of cyclin D-CDK4 activity in
macrophages and TGF-L-induced inhibition of cyclin
E-CDK2 in Mv1Lu mink epithelial cells [19,29].
However, the decrease in p27kip1 steady-state levels
in PDGF-BB-treated cells did not re£ect CDK4-
bound p27kip1 levels. On the other hand, PDGF-in-
duced depletion in p27kip1 levels resulted in a de-
crease in CDK2-bound p27kip1 levels. Analogous to
the present ¢ndings, a recent study showed that in-
creasing the cellular levels of p27kip1 severalfold by
transfecting cells with p27kip1 expression vector did
not lead to an increase in CDK4/6-bound p27kip1
levels and failed to inhibit these kinase activities.
Under the same conditions, more p27kip1 was found
to be associated with cyclin A-CDK2 and inhibited
its activity [30]. Based on these ¢ndings, it is conceiv-
able that cyclin E-CDK2 or cyclin A-CDK2 appear
to be sensitive to modulation by p27kip1. It is intrigu-
ing to note that although Ang II induced the expres-
sion of cyclin E, whose induction and complex for-
mation with, is required for CDK2 activity [11], it
failed to activate the enzyme. This ¢nding is appar-
ently due to Ang II’s inability to activate the signals
that are required for p27kip1 depletion. A similar sce-
nario was reported in Mv1Lu mink epithelial cells in
response to TGF-L [18,29]. Levels of cyclin E or
CDK2 were not a¡ected in TGF-L-treated cells com-
pared to levels in untreated cells. However, TGF-L
inhibited cyclin E-CDK2 activity, causing cells to
growth-arrest in G1, a ¢nding explained by increased
p27kip1 levels, which elevate the threshold level of
cyclin E to stably assemble with and activate
CDK2. Whatever the principle mechanism, in Ang
II-treated VSMC a correlation exists between lack of
depletion of p27kip1 levels and activation of CDK2. It
is also clear from our results that without a depletion
in p27kip1 levels, induction of expression of cyclin E
alone may not be su⁄cient to activate CDK2. The
case of PDGF-BB suggests this notion because there
is a correlation between p27kip1 depletion, cyclin E
expression and CDK2 activity.
A large body of evidence indicates that p21waf1=cip1
is a universal regulator of the cell cycle [17,31]. The
expression of p21waf1=cip1 has been shown to be in-
duced in response to a wide variety of DNA-damag-
ing agents, thereby causing inhibition of CDK activ-
ities [17,31]. It is of interest to note that both Ang II
and PDGF-BB, potent growth inducers, increased
the expression of p21waf1=cip1 in VSMC. The signi¢-
cance of the upregulation of p21waf1=cip1 by these
agents is, however, not clear. Induced expression of
p21waf1=cip1 in response to mitogens has also been
reported previously [32]. In a recent study it was
reported that the p21waf1=cip1 family of proteins,
present to certain threshold levels, are required for
facilitating functional kinase complex formation of
CDK4 with D1 cyclin [33]. It was also reported
that at higher levels these proteins are inhibitory to
kinase activity. In view of these ¢ndings, the ob-
served increases in p21waf1=cip1 levels in response to
Ang II and PDGF-BB may be demonstrated by its
role in the formation of the functional kinase com-
plex of CDK4 or 6 with type D cyclins, required
events for early cell cycle progression (e.g., G0 to
G1). If this was true, one would expect increased
CDK4 activity in response to Ang II, which was
not the case. This lack of e¡ect of Ang II on
CDK4 activity may be explained by its inability to
induce the expression of cyclin D1. On the other
hand, induced expression of p21waf1=cip1 may be in-
volved in the functional kinase complex formation of
CDKs such as CDK6 with other types of D cyclins
in response to Ang II. Another likely explanation for
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induced expression of p21waf1=cip1 by Ang II and
PDGF-BB is that its potential involvement in the
sequestration and downregulation of CDK activities
associated with early cell cycle progression as cells
advance to the next phase of the cell cycle. In fact,
a 2-fold increase in p21waf1=cip1 associated with
CDK4 at 10 h PDGF-BB treatment correlates with
decreased CDK4 activity. Future studies are needed
to delineate the role of p21waf1=cip1 in the modulation
of CDK activities by Ang II and PDGF-BB in
VSMC.
Recently, Coulonval et al. [34] reported that insu-
lin, a receptor tyrosine kinase agonist that causes
hypertrophy in thyrocytes, fails to phosphorylate
Rb. Our results also show a lack of e¡ect of Ang
II, a G protein-coupled receptor agonist and a hyper-
trophic agent, on the phosphorylation of Rb in
VSMC. The lack of e¡ect of Ang II on Rb phos-
phorylation appears to be due to its inability to acti-
vate G1 cyclin-CDKs such as cyclin D-CDK4 and
cyclin E-CDK2. However, it is unclear whether any
of the di¡erences in the signaling events observed
play a causal role in the lack of a mitogenic response
to Ang II. It is possible that Ang II-induced hyper-
trophy may not simply be due to its failure to acti-
vate a subset of mitogenic signaling events but rather
may be due to its activation of distinct growth re-
sponse events that are not stimulated by mitogens. In
any case, the present ¢ndings demonstrate a bifurca-
tion in cell cycle signaling events in response to hy-
pertrophic and hyperplastic agents, and establish the
basis for future investigations to elucidate the under-
lying mechanisms of hypertrophy and hyperplasia.
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